New! SARS-CoV-2 Nucleoprotein Polyclonal Antibodies Help to Detect Variants

North American Website Available!

It looks like you're accessing our website from North America. We have a dedicated page tailored to your region, offering the most relevant information and services.

If you have an existing eCom account, you can log in to the North American site using your current username and password.

Would you like to visit the North America page?

You can access the page here

If you have any questions, please feel free to contact our support team hytest@hytest.fi

New! SARS-CoV-2 Nucleoprotein Polyclonal Antibodies Help to Detect Variants

28.04.2021

undefined Polyclonal SARS-CoV-2 NP antibodies provide an excellent addition to the mix of antibodies to select for COVID-19 Antigen test development.

Our top priority in developing SARS-CoV-2 antibodies is to ensure that our antibodies and tests developed using our antibodies continue to detect the circulating virus variants. While we are confident that assays using a combination of our current monoclonal antibodies detect the main variants, we have now developed polyclonal antibodies specific to the nucleoprotein of SARS-CoV-2 as well. These polyclonal antibodies do not cross-react with seasonal coronaviruses and can be used in combination with our monoclonal anti-NP antibodies.

For test development, we recommend using more than two antibodies as multiple clones decrease the risk of future variants escaping the detection by the test.